vimarsana.com
Home
Live Updates
Ryvu Announces Dosing of the First Patient in the RIVER-52 P
Ryvu Announces Dosing of the First Patient in the RIVER-52 P
Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS
/PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address...
Related Keywords
Italy ,
Poland ,
Warsaw ,
L67 ,
Hendrik Nogai ,
Kamil Sitarz ,
European Union Clinical Trial Regulation ,
Menarini Group ,
Warsaw Stock Exchange ,
Development Plan ,
Chief Medical Officer ,
Ryvu Therapeutics ,
Chief Operating Officer ,
Competent Authorities ,
Ethics Committees ,